Latest news
- Business29 July 2020
Adalvo and Ambiopharm partner on development & licensing for key peptide products
Adalvo today announced that it has entered into partnership with AmbioPharm, a US-based pharmaceutical company, for an exclusive collaboration on the co-development and licensing for the commercialization of several complex...
- Business21 July 2020
Adalvo announces successful dual pivotal BE trial outcome of Solifenacin + Tamsulosin development
Adalvo is delighted to announce successful Fed and Fast Pivotal BE outcome of its Solifenacin + Tamsulosin development which demonstrates Adalvo's ability to continuously offer first-to-market opportunities to its valued...
- Business16 July 2020
Adalvo submits generic dossier applications for Icatibant pre-filled syringe
Adalvo today announces that it has submitted filings for generic dossier applications with the European Medicines Agency, seeking approval to market an Icatibant pre-filled syringe. Based on available information, Adalvo...
- Business29 June 2020
Adalvo announces positive CHMP opinion for Livogivatm (Teriparatide injection)
New commercialization agreement in Latin America announced with a large, multinational pharmaceutical firm.
- Business11 May 2020
Adalvo announces new strategic partnerships with Alvogen subsidiary
Adalvo, the new B2B company as part of the Alvogen and Alvotech family, have worked with Lotus pharmaceuticals in Asia to announce 10 new strategic partnership agreements in 2020 with...
- Business05 May 2020
Adalvo looking to create a buzz following its launch
Global pharmaceutical companies Alvogen and Alvotech have introduced a new corporate identity for its B2B operations – called Adalvo – following rapid growth in this area of business in the...
- Business26 March 2020
Message regarding Covid-19
We are living through a very challenging time. The Coronavirus spread is causing changes in everyday life and we are constantly monitoring the situation here at Adalvo
- Business24 March 2020
Alvogen submits European application for generic Pazopanib
Alvogen today announced that it has submitted generic dossier applications for Pazopanib tablets.
- Business24 March 2020
Alvotech and DKSH partner to bring key biosimilar to Asia
Alvotech Hf and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced that Alvotech Hf and DKSH have entered into an exclusive license partnership for...
- Business22 March 2020
Successful Kick Off meeting in Zurich
This February the Adalvo team got together in Zurich, Switzerland for a Kick Off meeting.
- Business
Adalvo & JSC Olainfarm to launch a new urology product in 17 countries in 2022-2023
Adalvo is delighted to partner with JSC Olainfarm to launch a new product within the urology segment which is targeted to be the 1st to market opportunity in 17 countries....